About
▼
Overview
Leadership
Our Team
Board of Directors
Investors
Science
▼
Overview
Highly Cytotoxic T Cells
KLRG1
Publications
Pipeline
▼
Overview
ABC008
IBM
T-LGLL
T and NK Cell Lymphomas
Additional Indications
ABC015
Clinical Trials
News
Careers
Contact
Abcuro
Breakthrough Therapies for Autoimmune Diseases & Cancer
About
Overview
Leadership
Our Team
Board of Directors
Investors
Science
Overview
Highly Cytotoxic T Cells
KLRG1
Publications
Pipeline
Overview
ABC008
IBM
T-LGLL
T and NK Cell Lymphomas
Additional Indications
ABC015
Clinical Trials
News
Careers
Contact
Eurofarma
August 17, 2023
